JP6469009B2 - がん処置用β−ヒドロキシラーゼ阻害剤 - Google Patents

がん処置用β−ヒドロキシラーゼ阻害剤 Download PDF

Info

Publication number
JP6469009B2
JP6469009B2 JP2015533237A JP2015533237A JP6469009B2 JP 6469009 B2 JP6469009 B2 JP 6469009B2 JP 2015533237 A JP2015533237 A JP 2015533237A JP 2015533237 A JP2015533237 A JP 2015533237A JP 6469009 B2 JP6469009 B2 JP 6469009B2
Authority
JP
Japan
Prior art keywords
compound
alkyl
substituted
unsubstituted
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015533237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015531351A5 (enExample
JP2015531351A (ja
Inventor
ジャック アール． ワンズ
ジャック アール． ワンズ
ラ モンテ スザンヌ デ
ラ モンテ スザンヌ デ
有弘 藍原
有弘 藍原
マーク ジョン オルセン
マーク ジョン オルセン
ジョン−マイケル トーマス
ジョン−マイケル トーマス
Original Assignee
ロード アイランド ホスピタル
ロード アイランド ホスピタル
ミッドウェスタン ユニバーシティ
ミッドウェスタン ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ロード アイランド ホスピタル, ロード アイランド ホスピタル, ミッドウェスタン ユニバーシティ, ミッドウェスタン ユニバーシティ filed Critical ロード アイランド ホスピタル
Publication of JP2015531351A publication Critical patent/JP2015531351A/ja
Publication of JP2015531351A5 publication Critical patent/JP2015531351A5/ja
Application granted granted Critical
Publication of JP6469009B2 publication Critical patent/JP6469009B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/66—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2015533237A 2012-09-21 2013-09-20 がん処置用β−ヒドロキシラーゼ阻害剤 Expired - Fee Related JP6469009B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261704014P 2012-09-21 2012-09-21
US61/704,014 2012-09-21
PCT/US2013/061050 WO2014047519A2 (en) 2012-09-21 2013-09-20 Inhibitors of beta-hydrolase for treatment of cancer

Publications (3)

Publication Number Publication Date
JP2015531351A JP2015531351A (ja) 2015-11-02
JP2015531351A5 JP2015531351A5 (enExample) 2016-11-10
JP6469009B2 true JP6469009B2 (ja) 2019-02-13

Family

ID=50342080

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015533237A Expired - Fee Related JP6469009B2 (ja) 2012-09-21 2013-09-20 がん処置用β−ヒドロキシラーゼ阻害剤

Country Status (10)

Country Link
US (8) US9771356B2 (enExample)
EP (2) EP3345596B1 (enExample)
JP (1) JP6469009B2 (enExample)
KR (1) KR102137180B1 (enExample)
CN (2) CN110818660B (enExample)
AU (1) AU2013317791B2 (enExample)
CA (1) CA2885762C (enExample)
ES (2) ES2865412T3 (enExample)
HK (1) HK1208805A1 (enExample)
WO (2) WO2014047447A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110818660B (zh) 2012-09-21 2023-09-12 罗得岛医院 用于治疗癌症的β-羟化酶抑制剂
WO2019012159A1 (en) * 2017-07-14 2019-01-17 Protea Biopharma N.V. METHODS AND MEANS FOR DIAGNOSING AND / OR TREATING A FATIGUE-ASSOCIATED DISEASE
US10961320B2 (en) 2018-06-18 2021-03-30 Midwestern University Monoclonal antibodies targeting epitopes of ASPH
CN109364251A (zh) * 2018-12-06 2019-02-22 苏州大学 Tet蛋白在治疗抑郁症中的应用
EP3923922A4 (en) 2019-02-15 2022-03-30 Midwestern University Isotopically-stabilized tetronimide compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE39717C (de) H. LEHMANN in München, Enhuberstr. 5 part Bleistifthalter
DD39717A (enExample) *
WO1987000729A1 (en) * 1985-08-02 1987-02-12 Chevron Research Company Herbicidal 2-(oxa or thia heterocycle)5-amino-3-oxo-4-(substituted-phenyl)-2,3-dihydrofurans
US5314913A (en) * 1992-12-08 1994-05-24 American Home Products Corporation 4- or 5-(substituted sulfonyl)methyl-3(2H)-furanones
JPH09110853A (ja) * 1995-10-12 1997-04-28 Kikkoman Corp ４‐アシルオキシフラノン誘導体又はその塩及びその製造方法
US5698585A (en) * 1995-04-13 1997-12-16 Kikkoman Corporation Pharmaceutical preparation for prevention and/or treatment for cataract
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
ATE244232T1 (de) * 1997-03-14 2003-07-15 Merck Frosst Canada Inc (methylsulfonyl)phenyl-2-(5h)-furanone mit sauerstoff-bindung als cox-2-hemmer
US20030031670A1 (en) 1999-11-08 2003-02-13 Jack R. Wands Diagnosis and treatment of malignant neoplasms
US6835370B2 (en) 1999-11-08 2004-12-28 Rhode Island Hospital Diagnosis and treatment of malignant neoplasms
US20050123545A1 (en) 1999-11-08 2005-06-09 Wands Jack R. Diagnosis and treatment of malignant neoplasms
WO2003018575A1 (en) 2001-08-24 2003-03-06 Wyeth Holdings Corporation 5-substituted-3(2h)-furanones useful for inhibition of farnesyl-protein transferase
US6667330B2 (en) 2002-01-31 2003-12-23 Galileo Pharmaceuticals, Inc. Furanone derivatives
AU2002950862A0 (en) * 2002-08-19 2002-09-12 Biosignal Pty Ltd Furanone derivatives and methods of making same
DE60330587D1 (de) * 2002-10-16 2010-01-28 Isis Innovation Screening-Methoden unter Verwendung eines Strukturmodells von FIH
WO2005070916A1 (en) * 2004-01-09 2005-08-04 Eli Lilly And Company Thiophene and furan compounds
EP2227233B1 (en) 2007-11-30 2013-02-13 Newlink Genetics Ido inhibitors
EP2576532B1 (en) * 2010-06-07 2018-07-18 Novomedix, LLC Furanyl compounds and the use thereof
CN110818660B (zh) 2012-09-21 2023-09-12 罗得岛医院 用于治疗癌症的β-羟化酶抑制剂

Also Published As

Publication number Publication date
ES2865412T3 (es) 2021-10-15
CA2885762C (en) 2022-05-03
ES2660822T3 (es) 2018-03-26
CA2885762A1 (en) 2014-03-27
US10710995B2 (en) 2020-07-14
US10787445B2 (en) 2020-09-29
US20150210677A1 (en) 2015-07-30
US20190002453A1 (en) 2019-01-03
WO2014047519A2 (en) 2014-03-27
US10351555B2 (en) 2019-07-16
US20220251076A1 (en) 2022-08-11
US20210032233A1 (en) 2021-02-04
KR20150079616A (ko) 2015-07-08
US9771356B2 (en) 2017-09-26
WO2014047447A2 (en) 2014-03-27
CN110818660A (zh) 2020-02-21
AU2013317791B2 (en) 2018-05-10
EP3345596B1 (en) 2021-01-20
HK1208805A1 (zh) 2016-03-18
EP2897607A2 (en) 2015-07-29
US20190300519A1 (en) 2019-10-03
US20180009798A1 (en) 2018-01-11
US10106532B2 (en) 2018-10-23
US20180237427A1 (en) 2018-08-23
EP3345596A3 (en) 2018-10-03
WO2014047519A3 (en) 2014-05-30
EP3345596A2 (en) 2018-07-11
WO2014047447A3 (en) 2015-07-30
AU2013317791A1 (en) 2015-05-07
KR102137180B1 (ko) 2020-07-24
EP2897607A4 (en) 2016-10-05
CN110818660B (zh) 2023-09-12
JP2015531351A (ja) 2015-11-02
US20200361925A1 (en) 2020-11-19
EP2897607B1 (en) 2017-11-22
CN104902889A (zh) 2015-09-09

Similar Documents

Publication Publication Date Title
JP6779793B2 (ja) リンパ腫を治療するためのｅｚｈ２阻害剤
US20220251076A1 (en) Inhibitors of Beta-Hydoxylase for Treatment of Cancer
CN102424681B (zh) 酰基四氢-β-咔啉类化合物及其衍生物、用途及其制备方法
KR102338568B1 (ko) 퀴나졸린 유도체
JPWO2006104161A1 (ja) ｃ−Ｍｅｔ自己リン酸化阻害作用を有するチエノピリジン誘導体、キノリン誘導体、およびキナゾリン誘導体
JPWO2002066073A1 (ja) インテグリン発現抑制を介した血管新生抑制剤の効果を検定する方法
US11897857B2 (en) Isotopically-stabilized tetronimide compounds
US20210052561A1 (en) Targeting aspartate beta-hydroxylase suppresses tumor malignancy and metastasis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170524

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180807

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190115

R150 Certificate of patent or registration of utility model

Ref document number: 6469009

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees